Dr. Reddy’s Laboratories Ltd. ADR (RDY) Stock: A Closer Look at the Market Potential

The price-to-earnings ratio for Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) is above average at 18.57x, Company’s 36-month beta value is 0.54.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for RDY is 834.06M, and currently, short sellers hold a 1.28% ratio of that floaft. The average trading volume of RDY on November 15, 2024 was 763.95K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

RDY) stock’s latest price update

The stock of Dr. Reddy’s Laboratories Ltd. ADR (NYSE: RDY) has decreased by -2.20 when compared to last closing price of 14.56. Despite this, the company has experienced a -5.63% fall in its stock price over the last five trading sessions. zacks.com reported 2024-11-06 that RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time acquisition cost and impairment charge on non-current assets.

RDY’s Market Performance

Dr. Reddy’s Laboratories Ltd. ADR (RDY) has experienced a -5.63% fall in stock performance for the past week, with a -10.10% drop in the past month, and a -12.93% drop in the past quarter. The volatility ratio for the week is 1.57%, and the volatility levels for the past 30 days are at 1.78% for RDY. The simple moving average for the last 20 days is -5.87% for RDY stock, with a simple moving average of -6.30% for the last 200 days.

RDY Trading at -8.41% from the 50-Day Moving Average

After a stumble in the market that brought RDY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.70% of loss for the given period.

Volatility was left at 1.78%, however, over the last 30 days, the volatility rate increased by 1.57%, as shares sank -10.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.60% lower at present.

During the last 5 trading sessions, RDY fell by -5.63%, which changed the moving average for the period of 200-days by -1.04% in comparison to the 20-day moving average, which settled at $15.13. In addition, Dr. Reddy’s Laboratories Ltd. ADR saw 2.33% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RDY starting from Israeli Erez, who proposed sale 65,500 shares at the price of $82.29 back on Jul 29 ’24. After this action, Israeli Erez now owns shares of Dr. Reddy’s Laboratories Ltd. ADR, valued at $5,390,000 using the latest closing price.

Stock Fundamentals for RDY

Current profitability levels for the company are sitting at:

  • 0.23 for the present operating margin
  • 0.59 for the gross margin

The net margin for Dr. Reddy’s Laboratories Ltd. ADR stands at 0.18. The total capital return value is set at 0.2. Equity return is now at value 19.12, with 13.14 for asset returns.

Based on Dr. Reddy’s Laboratories Ltd. ADR (RDY), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at 0.78. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is 64.13.

Currently, EBITDA for the company is 82.57 billion with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 3.47. The receivables turnover for the company is 2.92for trailing twelve months and the total asset turnover is 0.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.92.

Conclusion

In a nutshell, Dr. Reddy’s Laboratories Ltd. ADR (RDY) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts